
Triple-receptor agonist · 20mg formulation
Retatrutide at intermediate dosage — for clients progressing through the Lumeva step-up metabolic protocol.
Intermediate-dose triple-receptor agonist providing enhanced GLP-1, GIP, and glucagon receptor engagement for advanced metabolic support.
The RT20 Protocol represents the intermediate tier of the Retatrutide dose-escalation programme. Building on RT10 initiation, the 20mg dose provides enhanced receptor engagement across all three pathways.
Clients progressing to RT20 typically have completed an RT10 initiation cycle and have been assessed by their Lumeva consultant as suitable for dose progression based on their response and biomarker profile.
The step-up approach to Retatrutide dosing is central to the Lumeva Method — ensuring your metabolic wellness journey is both effective and appropriately monitored at every stage.
Every Lumeva protocol is manufactured using advanced synthesis techniques within controlled laboratory environments. Carries ≥99.9% purity certification and full batch-specific QA documentation.
Consult with our experts to confirm your readiness for the RT20 intermediate dose progression.